ID: ALA440405

Max Phase: Preclinical

Molecular Formula: C20H18FN3O3S

Molecular Weight: 399.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  CS(=O)(=O)NC(=O)CCCc1c(-c2ccc(F)cc2)[nH]c2ccc(C#N)cc12

Standard InChI:  InChI=1S/C20H18FN3O3S/c1-28(26,27)24-19(25)4-2-3-16-17-11-13(12-22)5-10-18(17)23-20(16)14-6-8-15(21)9-7-14/h5-11,23H,2-4H2,1H3,(H,24,25)

Standard InChI Key:  OVTPSSRHMPJRCX-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 399.45

Molecular Weight (Monoisotopic): 399.1053

AlogP: 3.24

#Rotatable Bonds: 6

Polar Surface Area: 102.82

Molecular Species: ACID

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 4.08

CX Basic pKa:

CX LogP: 2.84

CX LogD: 1.90

Aromatic Rings: 3

Heavy Atoms: 28

QED Weighted: 0.66

Np Likeness Score: -1.11

References

1. Winters MP, Crysler C, Subasinghe N, Ryan D, Leong L, Zhao S, Donatelli R, Yurkow E, Mazzulla M, Boczon L, Manthey CL, Molloy C, Raymond H, Murray L, McAlonan L, Tomczuk B..  (2008)  Carboxylic acid bioisosteres acylsulfonamides, acylsulfamides, and sulfonylureas as novel antagonists of the CXCR2 receptor.,  18  (6): [PMID:18308567] [10.1016/j.bmcl.2008.01.127]

2. Mark Wenlock and Nicholas Tomkinson. Experimental in vitro DMPK and physicochemical data on a set of publicly disclosed compounds,  [10.6019/CHEMBL3301361]

Source

Source(2):

• Scientific Literature
• AstraZeneca Deposited Data